EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR
EPA:ALVAL (3/7/2025, 7:00:00 PM)
1.084
+0.01 (+1.31%)
The current stock price of ALVAL.PA is 1.084 EUR. In the past month the price decreased by -20.53%. In the past year, price decreased by -72.9%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 52 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
VALBIOTIS SAS
12F rue Paul Vatine
Perigny NOUVELLE-AQUITAINE FR
Employees: 52
Company Website: https://www.valbiotis.com/
Investor Relations: https://www.valbiotis.com/en/investors/#financial3
The current stock price of ALVAL.PA is 1.084 EUR. The price increased by 1.31% in the last trading session.
The exchange symbol of VALBIOTIS SAS is ALVAL and it is listed on the Euronext Paris - Matif exchange.
ALVAL.PA stock is listed on the Euronext Paris - Matif exchange.
10 analysts have analysed ALVAL.PA and the average price target is 5.34 EUR. This implies a price increase of 392.43% is expected in the next year compared to the current price of 1.084. Check the VALBIOTIS SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VALBIOTIS SAS (ALVAL.PA) has a market capitalization of 17.12M EUR. This makes ALVAL.PA a Nano Cap stock.
VALBIOTIS SAS (ALVAL.PA) currently has 52 employees.
VALBIOTIS SAS (ALVAL.PA) has a resistance level at 1.55. Check the full technical report for a detailed analysis of ALVAL.PA support and resistance levels.
The Revenue of VALBIOTIS SAS (ALVAL.PA) is expected to decline by -96.57% in the next year. Check the estimates tab for more information on the ALVAL.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALVAL.PA does not pay a dividend.
VALBIOTIS SAS (ALVAL.PA) will report earnings on 2025-04-25, after the market close.
VALBIOTIS SAS (ALVAL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.66).
ChartMill assigns a fundamental rating of 3 / 10 to ALVAL.PA. While ALVAL.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 22.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -34.58% | ||
ROE | -53.12% | ||
Debt/Equity | 0.24 |
ChartMill assigns a Buy % Consensus number of 84% to ALVAL.PA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -2.92% and a revenue growth -96.57% for ALVAL.PA